What the studies measured, how to train, and how much protein to eat when you’re not hungry.
Find Your Body ProtocolAny meaningful weight loss, whether from diet, surgery or medication, takes some lean mass with it, and studies of Tirzepatide show the same pattern; an MRI study found muscle changes roughly in line with the amount of weight lost. The best-supported ways to protect muscle are regular resistance training and enough protein, which a 2025 joint advisory from four obesity and nutrition societies puts at roughly 1.2 to 1.6 g per kg a day during active weight loss. Your physician sets your dose; your training and food are what you control.
Body composition scans in the Tirzepatide trials (DXA in a weight-loss trial, MRI in a diabetes trial) found that most of the weight lost was fat, and that some lean mass was lost too. In the MRI substudy, the muscle changes were roughly what you’d expect for the amount of weight lost.
Two caveats: “lean mass” on a scan includes water and organs, not just muscle, and most trial participants weren’t following a structured lifting program. These studies don’t tell you what happens to a man who trains hard and eats enough protein.
The evidence points to the weight loss. Losing weight by any route usually takes some lean mass with it. That’s why training and protein matter on any fat-loss plan, with or without medication.
Lift, and keep lifting. Resistance training is the strongest signal you can send your body to keep muscle.
The 2025 joint advisory suggests roughly 1.2 to 1.6 g of protein per kg of body weight a day during active weight loss. In plain numbers:
When you’re not hungry, eat the protein first: eggs, Greek yogurt, lean meat, fish, or a shake. Your physician may adjust this if you have kidney problems.
Message your care team if you notice weakness that keeps getting worse, dizziness or fainting, you can’t eat enough to train, or your strength is dropping week after week. Those are reasons to review your dose and your plan, not to push through.
Prescription required. A licensed physician decides whether compounded Tirzepatide is appropriate for you, and your dose.
Boxed warning: risk of thyroid C-cell tumors. In animal studies, Tirzepatide caused thyroid C-cell tumors. It is unknown whether it causes these tumors, including medullary thyroid carcinoma (MTC), in people. Do not use Tirzepatide if you or a family member have ever had MTC, or if you have Multiple Endocrine Neoplasia syndrome type 2 (MEN 2).
Possible serious side effects include inflammation of the pancreas (pancreatitis), gallbladder problems, low blood sugar (especially with insulin or a sulfonylurea), kidney problems from dehydration and serious allergic reactions.
The most common side effects are nausea, diarrhea, vomiting, constipation, stomach pain, indigestion and decreased appetite.
Compounded medications are not FDA-approved. The FDA does not review compounded drugs for safety, effectiveness or quality. Compounded Tirzepatide is prepared by Strive Pharmacy, a state-licensed 503A compounding pharmacy. Not available in Arkansas, Indiana or South Carolina.
Two minutes of questions, then a short medical intake. A licensed physician decides whether compounded Tirzepatide is appropriate for you, and your dose. Not approved? Full refund.